MINI LONG - ROCHE GS Share Price

Certificat

DE000CT7JS03

Delayed Börse Stuttgart 08:14:23 30/04/2024 BST
6.23 EUR -1.74% Intraday chart for MINI LONG - ROCHE GS
Current month-13.11%
1 month-13.11%
Date Price Change Volume
30/04/24 6.23 -1.74% 0
29/04/24 6.34 +2.26% 0
26/04/24 6.2 -3.43% 0
25/04/24 6.42 -3.60% 0
24/04/24 6.66 -6.98% 0

Delayed Quote Börse Stuttgart

Last update April 30, 2024 at 08:14 am

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Citi Citi
WKN CT7JS0
ISINDE000CT7JS03
Date issued 16/08/2012
Strike 159.3 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 0.95
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 24.15
Lowest since issue 0.63

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
220.6 CHF
Average target price
279.1 CHF
Spread / Average Target
+26.50%
Consensus